Surinabant

Surinabant

Systematic (IUPAC) name
5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide
Identifiers
CAS Number	288104-79-0 N
ATC code	none
PubChem	CID: 9849616
ChemSpider	8025329 Y
UNII	SF8R9VCB0X Y
ChEMBL	CHEMBL189676 Y
Chemical data
Formula	C23H23BrCl2N4O
Molecular mass	522.264 g/mol
SMILES O=C(NN1CCCCC1)c4nn(c2ccc(Cl)cc2Cl)c(c3ccc(Br)cc3)c4CC
InChI InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31) Y Key:HMXDWDSNPRNUKI-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Surinabant (SR147778) is a cannabinoid receptor type 1 antagonist developed by Sanofi-Aventis. It is being investigated as a potential treatment for nicotine addiction, to assist smoking cessation. It may also be developed as an anorectic drug to assist with weight loss, however there are already several CB₁ antagonists or inverse agonists on the market or under development for this application, so surinabant is at present mainly being developed as an anti-smoking drug, with possible application in the treatment of other addictive disorders such as alcoholism. Other potential applications such as treatment of ADHD have also been proposed.

A dose ranging study was done for smoking cessation in 2012; it did not improve success rate, but reduced weight gain. Inhibition of THC effects on heart rate was seen at 20 mg and 60 mg but not 5 mg.

See also

• Cannabinoid receptor antagonist
• O-1269